Chronic viral hepatitis may diminish the gains of HIV antiretroviral therapy in sub-Saharan Africa

Citations Over TimeTop 18% of 2008 papers

Abstract

There is a heavy burden of HIV-hepatitis B virus (HBV) and HIV-hepatitis C virus (HCV) co-infection in many regions of the developing world. An often unmentioned illness, issues of poverty, socio-economic status, nutrition, access to medical care, and mistrust of Western-style medicine conspire to reduce the opportunity to receive clinical work-up and treatment for chronic viral hepatitis. We discuss key issues specific to the treatment of viral hepatitis and obstacles to success with this endeavor in the context of HIV co-infection in Africa. We predict that provision of viral hepatitis antiviral therapy will become a more pressing issue as more HIV-infected patients receive lifesaving combination antiretroviral therapy only to succumb thereafter from viral hepatitis-induced liver disease. Given the lessons learned from combination antiretroviral rollout in sub-Saharan Africa, establishing expertise and infrastructure for viral hepatitis care and antiviral therapy is relevant. Failure to act now may diminish the milestones and the gains made with antiretroviral therapy in the developing world.

Related Papers

• → The Relation Between Symptoms, Viral Load, and Viral Load Set Point in Primary HIV Infection(2007)88 cited
• → Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure?(2002)42 cited
• → Lack of evidence of a stable viral load set-point in early stage asymptomatic patients with chronic HIV-1 infection(1998)21 cited
• → Assessment of the Cavidi ExaVir Load Assay for Monitoring Plasma Viral Load in HIV-2-Infected Patients(2017)6 cited
• → Near point-of-care HIV viral load testing: Uptake and utilization in suburban Yangon, Myanmar(2022)